D. Gretler

发表

PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers

A. Rani, S. Jurcevic, A. Betz, 2016, Journal of clinical pharmacology.

Ethnic differences in circadian hemodynamic profile.

M. Murphy, D. Gretler, M. Fumo, 1994, American journal of hypertension.

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI

Deepak L. Bhatt, Sunil V. Rao, K. Huber, 2010, American heart journal.

Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension.

W. Elliott, M. Murphy, D. Gretler, 1990, Circulation.

Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)

M. Ezekowitz, S. Connolly, S. Hohnloser, 2013, European heart journal.

Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients.

Deepak L. Bhatt, H. Dauerman, R. Becker, 2010, American heart journal.

A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention: The INNOVATE-PCI Trial

Deepak L. Bhatt, Sunil V. Rao, K. Huber, 2012, Circulation. Cardiovascular interventions.

Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intra

P. Armstrong, C. Granger, C. Grines, 2009, American heart journal.

Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience.

R. Califf, R. Diaz, E. Topol, 1999, Circulation.

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.

K. Dufu, J. Howard, P. Telfer, 2019, Blood.

Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin.

D. Gretler, 2003, Clinical therapeutics.

Influence of Diuretic Therapy on the Clonidine Suppression Test

G. Gramelspacher, W. Elliott, M. Murphy, 1991, Journal of clinical pharmacology.

Pharmacodynamics and Pharmacokinetics of Eptifibatide in Patients With Acute Coronary Syndromes: Prospective Analysis From PURSUIT

A. Lincoff, R. Harrington, N. Kleiman, 2001, Circulation.

A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)

M. Gent, A. Turpie, K. Bauer, 2008, Thrombosis and Haemostasis.

Electrocardiographic changes during acute treatment of hypertensive emergencies with sodium nitroprusside or fenoldopam.

R. Childers, M. Moscucci, W. Elliott, 1992, Archives of internal medicine.

Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.

Paul J. Williams, R. Guerciolini, D. Gretler, 2004, Clinical therapeutics.

First‐in‐Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers

J. Fox, J. Jernelius, Jennifer L. Hellawell, 2019, Clinical pharmacology in drug development.

The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial.

S. Stevens, Mauricio G. Cohen, J. Alexander, 2011, American heart journal.

Diurnal blood pressure variation: differences among disparate ethnic groups.

R. M. Lang, M. Murphy, D. Gretler, 1991, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease

C. Washington, A. Hutchaleelaha, D. Oksenberg, 2019, British journal of clinical pharmacology.

Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.

R. Scarborough, D. Gretler, Robert M. Scarborough, 2000, Journal of medicinal chemistry.

Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.

D D Gretler, R. Scarborough, R M Scarborough, 2000, Journal of medicinal chemistry.

Randomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes: The COMPARE Trial

M. Davidian, R. Califf, E. Ohman, 2002, Circulation.

Strophanthidin and potassium on intracellular sodium activity in sheep heart.

D. Gretler, 1985, Journal of molecular and cellular cardiology.

Thrombocytopenia in a large, international trial of the GP IIb/IIIa inhibitor eptitibatide in patients with acute coronary syndromes

R. Diaz, K. Karsch, R. Harrington, 1998 .

Comparison of receptor occupancy and platelet aggregation response of eptifibatide administered intravenously in patients with unstable angina or non-Q-wave myocardial infarction

L. Jennings, D. Phillips, B. Tardiff, 1998 .

Noninvasive method for determination of arterial compliance using Doppler echocardiography and subclavian pulse tracings. Validation and clinical application of a physiological model of the circulation.

L Weinert, L. Weinert, K. Borow, 1994, Circulation.

The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to cyp 2c19*2 genotype: first experience in patients

A. Shuldiner, P. Gurbel, U. Tantry, 2010, Journal of thrombosis and haemostasis : JTH.

Diurnal blood pressure variability and physical activity measured electronically and by diary.

D D Gretler, M. Murphy, M B Murphy, 1993, American journal of hypertension.

Cerebral blood flow during the acute therapy of severe hypertension with oral clonidine.

M. Murphy, F. Brown, C. E. McCoy, 1990, The American journal of emergency medicine.

5-Hydroxytryptamine receptor activity of the dopamine receptor agonist fenoldopam in canine tracheal smooth muscle.

M. Murphy, D. Gretler, K. C. Jones, 1992, Journal of Pharmacology and Experimental Therapeutics.

Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study

J. Morganroth, S. Hollenbach, U. Sinha, 2013, Expert opinion on pharmacotherapy.

Low predictive value of positive Osler manoeuvre for diagnosing pseudohypertension.

W. Elliott, M. Murphy, D. Gretler, 1993, Journal of human hypertension.

PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers

S. Jurcevic, A. Betz, A. Pandey, 2016, Journal of clinical pharmacology.

AG10, A Novel, Potent and Selective Transthyretin Stabilizer, is Well Tolerated at Doses Resulting in Target Therapeutic Blood Levels, and Demonstrates Clinical Proof-of-Concept in Healthy Volunteers

J. Fox, J. Jernelius, Jennifer L. Hellawell, 2018, Journal of Cardiac Failure.

The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to cyp 2c19*2 genotype: first experience in patients

A. Shuldiner, P. Gurbel, U. Tantry, 2010, Journal of thrombosis and haemostasis : JTH.

INITIAL INTRAVENOUS EXPERIENCE WITH PRT060128 (PRT128), AN ORALLY-AVAILABLE, DIRECT-ACTING, AND REVERSIBLE P2Y12 INHIBITOR

P. Conley, D. Phillips, P. Leese, 2007 .

A Novel Pharmacodynamic Perfusion Chamber Assay Reveals Superior and Unique Antithrombotic Activities of a Direct-Acting P2Y12 Antagonist, PRT128, Relative to Clopidogrel.

A. Finn, H. Gold, P. Conley, 2006 .

Deepak L. Bhatt, K. Huber, R. Harrington, 2012, Circulation. Cardiovascular interventions.

Abstract 5603: Oral Dosing of PRT060128, a Novel Direct-acting, Reversible P2Y12 Antagonist Overcomes High Platelet Reactivity in Patients Non-responsive to Clopidogrel Therapy

P. Gurbel, U. Tantry, P. Conley, 2008 .